kaplan-meier estimated survival Search Results


90
SAS institute product-limit survival estimate based on the kaplan-meier survival platform
Product Limit Survival Estimate Based On The Kaplan Meier Survival Platform, supplied by SAS institute, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/kaplan-meier+estimated+survival/10__1653_slash_024__094__0430-78-21-24?v=SAS+institute
Average 90 stars, based on 1 article reviews
product-limit survival estimate based on the kaplan-meier survival platform - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

90
PharMetrics Inc kaplan-meier estimated survival
Kaplan Meier Estimated Survival, supplied by PharMetrics Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/kaplan-meier+estimated+survival/pmc10408410-255-7-11?v=PharMetrics+Inc
Average 90 stars, based on 1 article reviews
kaplan-meier estimated survival - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

90
SAS institute kaplan-meier estimate of the survival function of the censoring variable
Kaplan Meier Estimate Of The Survival Function Of The Censoring Variable, supplied by SAS institute, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/kaplan-meier+estimated+survival/pm36841041-132-9-38?v=SAS+institute
Average 90 stars, based on 1 article reviews
kaplan-meier estimate of the survival function of the censoring variable - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

90
MBL Life science kaplan-meier estimator of progression-free (pf) survival (pfs) since diagnosis
Kaplan Meier Estimator Of Progression Free (Pf) Survival (Pfs) Since Diagnosis, supplied by MBL Life science, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/kaplan-meier+estimated+survival/pm33730576-67-8-22?v=MBL+Life+science
Average 90 stars, based on 1 article reviews
kaplan-meier estimator of progression-free (pf) survival (pfs) since diagnosis - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

90
GraphPad Software Inc kaplan meier survival estimate
Kaplan Meier Survival Estimate, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/kaplan-meier+estimated+survival/pm37085564-132-11-16?v=GraphPad+Software+Inc
Average 90 stars, based on 1 article reviews
kaplan meier survival estimate - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

90
Johns Hopkins HealthCare kaplan-meier estimates of recurrence-free survival of esophageal cancer patients
Kaplan-Meier Estimates of Recurrence-Free Survival of <t>Esophageal</t> Cancer Patients (n=261) at the Johns Hopkins Hospital, according to Pathological Response at Time of Surgical Resection.
Kaplan Meier Estimates Of Recurrence Free Survival Of Esophageal Cancer Patients, supplied by Johns Hopkins HealthCare, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/kaplan-meier+estimated+survival/pmc03654695-255-65-71?v=Johns+Hopkins+HealthCare
Average 90 stars, based on 1 article reviews
kaplan-meier estimates of recurrence-free survival of esophageal cancer patients - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

90
Addinsoft inc kaplan–meier estimator of the survival function xlstatlife software
Kaplan-Meier Estimates of Recurrence-Free Survival of <t>Esophageal</t> Cancer Patients (n=261) at the Johns Hopkins Hospital, according to Pathological Response at Time of Surgical Resection.
Kaplan–Meier Estimator Of The Survival Function Xlstatlife Software, supplied by Addinsoft inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/kaplan-meier+estimated+survival/pm25503984-51-17-21?v=Addinsoft+inc
Average 90 stars, based on 1 article reviews
kaplan–meier estimator of the survival function xlstatlife software - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

90
Verlag GmbH kaplan-meier survival estimates bias version 11.06
Kaplan-Meier Estimates of Recurrence-Free Survival of <t>Esophageal</t> Cancer Patients (n=261) at the Johns Hopkins Hospital, according to Pathological Response at Time of Surgical Resection.
Kaplan Meier Survival Estimates Bias Version 11.06, supplied by Verlag GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/kaplan-meier+estimated+survival/pm32960329-75-27-30?v=Verlag+GmbH
Average 90 stars, based on 1 article reviews
kaplan-meier survival estimates bias version 11.06 - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

90
TIBCO kaplan–meier survival estimator
Kaplan-Meier Estimates of Recurrence-Free Survival of <t>Esophageal</t> Cancer Patients (n=261) at the Johns Hopkins Hospital, according to Pathological Response at Time of Surgical Resection.
Kaplan–Meier Survival Estimator, supplied by TIBCO, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/kaplan-meier+estimated+survival/pm30111844-37-9-26?v=TIBCO
Average 90 stars, based on 1 article reviews
kaplan–meier survival estimator - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

Image Search Results


Kaplan-Meier Estimates of Recurrence-Free Survival of Esophageal Cancer Patients (n=261) at the Johns Hopkins Hospital, according to Pathological Response at Time of Surgical Resection.

Journal: The Journal of thoracic and cardiovascular surgery

Article Title: Recurrence after Neoadjuvant Chemoradiation and Surgery for Esophageal Cancer: Does the Pattern of Recurrence Differ for Complete Responders and Those with Partial or No response?

doi: 10.1016/j.jtcvs.2009.07.069

Figure Lengend Snippet: Kaplan-Meier Estimates of Recurrence-Free Survival of Esophageal Cancer Patients (n=261) at the Johns Hopkins Hospital, according to Pathological Response at Time of Surgical Resection.

Article Snippet: Thus, these data suggest that neoadjuvant chemoradiation delayed recurrence significantly and as well fewer patients failed (p=0.055). showing freedom from recurrence again underscores the fact that patients with CR have a significantly longer disease-free interval than patients with PR and NR (p=0.01). fig ft0 fig mode=article f1 fig/graphic|fig/alternatives/graphic mode="anchored" m1 Open in a separate window Figure 1 caption a7 Kaplan-Meier Estimates of Recurrence-Free Survival of Esophageal Cancer Patients (n=261) at the Johns Hopkins Hospital, according to Pathological Response at Time of Surgical Resection. table ft1 table-wrap mode="anchored" t5 caption a7 Complete Response Partial Response No Response P value Median IQR Median IQR Median IQR Within Radiation Field 5.8 4.7 - 9.3 7.1 3.5 - 18 8.5 7.5 - 62.3 0.604 Outside Radiation Field 27.3 12.3 - 31.1 5.7 3.9 - 15.8 9.1 6.9 - 14.5 0.008 Open in a separate window Median Disease-Free Survival of Patients with Recurrence (N=84) This impact of chemoradiation in preventing recurrence was of sufficient magnitude also to impact survival.

Techniques:

Kaplan-Meier Estimates of Overall Survival of Esophageal Cancer Patients (n=267) at the Johns Hopkins Hospital, according to Pathological Response at Time of Surgical Resection. The Kaplan-Meier estimates for overall survival indicate that as the extent of pathological response to neoadjuvant therapy increases, there is a significant increase in the overall survival of the patient. It is interesting to note, however, that in our observed cohort, the degree of pathological response to neoadjuvant therapy seemed not to affect patients with early mortality (<10 months) but rather those who survived more than one year.

Journal: The Journal of thoracic and cardiovascular surgery

Article Title: Recurrence after Neoadjuvant Chemoradiation and Surgery for Esophageal Cancer: Does the Pattern of Recurrence Differ for Complete Responders and Those with Partial or No response?

doi: 10.1016/j.jtcvs.2009.07.069

Figure Lengend Snippet: Kaplan-Meier Estimates of Overall Survival of Esophageal Cancer Patients (n=267) at the Johns Hopkins Hospital, according to Pathological Response at Time of Surgical Resection. The Kaplan-Meier estimates for overall survival indicate that as the extent of pathological response to neoadjuvant therapy increases, there is a significant increase in the overall survival of the patient. It is interesting to note, however, that in our observed cohort, the degree of pathological response to neoadjuvant therapy seemed not to affect patients with early mortality (<10 months) but rather those who survived more than one year.

Article Snippet: Thus, these data suggest that neoadjuvant chemoradiation delayed recurrence significantly and as well fewer patients failed (p=0.055). showing freedom from recurrence again underscores the fact that patients with CR have a significantly longer disease-free interval than patients with PR and NR (p=0.01). fig ft0 fig mode=article f1 fig/graphic|fig/alternatives/graphic mode="anchored" m1 Open in a separate window Figure 1 caption a7 Kaplan-Meier Estimates of Recurrence-Free Survival of Esophageal Cancer Patients (n=261) at the Johns Hopkins Hospital, according to Pathological Response at Time of Surgical Resection. table ft1 table-wrap mode="anchored" t5 caption a7 Complete Response Partial Response No Response P value Median IQR Median IQR Median IQR Within Radiation Field 5.8 4.7 - 9.3 7.1 3.5 - 18 8.5 7.5 - 62.3 0.604 Outside Radiation Field 27.3 12.3 - 31.1 5.7 3.9 - 15.8 9.1 6.9 - 14.5 0.008 Open in a separate window Median Disease-Free Survival of Patients with Recurrence (N=84) This impact of chemoradiation in preventing recurrence was of sufficient magnitude also to impact survival.

Techniques:

Kaplan-Meier Estimates of Overall Survival of Esophageal Cancer Patients who had a complete pathological response to neoadjuvant therapy (n=82) at the Johns Hopkins Hospital, according to whether or not there was cancer recurrence following surgical resection.

Journal: The Journal of thoracic and cardiovascular surgery

Article Title: Recurrence after Neoadjuvant Chemoradiation and Surgery for Esophageal Cancer: Does the Pattern of Recurrence Differ for Complete Responders and Those with Partial or No response?

doi: 10.1016/j.jtcvs.2009.07.069

Figure Lengend Snippet: Kaplan-Meier Estimates of Overall Survival of Esophageal Cancer Patients who had a complete pathological response to neoadjuvant therapy (n=82) at the Johns Hopkins Hospital, according to whether or not there was cancer recurrence following surgical resection.

Article Snippet: Thus, these data suggest that neoadjuvant chemoradiation delayed recurrence significantly and as well fewer patients failed (p=0.055). showing freedom from recurrence again underscores the fact that patients with CR have a significantly longer disease-free interval than patients with PR and NR (p=0.01). fig ft0 fig mode=article f1 fig/graphic|fig/alternatives/graphic mode="anchored" m1 Open in a separate window Figure 1 caption a7 Kaplan-Meier Estimates of Recurrence-Free Survival of Esophageal Cancer Patients (n=261) at the Johns Hopkins Hospital, according to Pathological Response at Time of Surgical Resection. table ft1 table-wrap mode="anchored" t5 caption a7 Complete Response Partial Response No Response P value Median IQR Median IQR Median IQR Within Radiation Field 5.8 4.7 - 9.3 7.1 3.5 - 18 8.5 7.5 - 62.3 0.604 Outside Radiation Field 27.3 12.3 - 31.1 5.7 3.9 - 15.8 9.1 6.9 - 14.5 0.008 Open in a separate window Median Disease-Free Survival of Patients with Recurrence (N=84) This impact of chemoradiation in preventing recurrence was of sufficient magnitude also to impact survival.

Techniques:

Kaplan-Meier Estimates of Overall Survival of Esophageal Cancer Patients who had a partial pathological response to neoadjuvant therapy (n=108) at the Johns Hopkins Hospital, according to whether or not there was cancer recurrence following surgical resection.

Journal: The Journal of thoracic and cardiovascular surgery

Article Title: Recurrence after Neoadjuvant Chemoradiation and Surgery for Esophageal Cancer: Does the Pattern of Recurrence Differ for Complete Responders and Those with Partial or No response?

doi: 10.1016/j.jtcvs.2009.07.069

Figure Lengend Snippet: Kaplan-Meier Estimates of Overall Survival of Esophageal Cancer Patients who had a partial pathological response to neoadjuvant therapy (n=108) at the Johns Hopkins Hospital, according to whether or not there was cancer recurrence following surgical resection.

Article Snippet: Thus, these data suggest that neoadjuvant chemoradiation delayed recurrence significantly and as well fewer patients failed (p=0.055). showing freedom from recurrence again underscores the fact that patients with CR have a significantly longer disease-free interval than patients with PR and NR (p=0.01). fig ft0 fig mode=article f1 fig/graphic|fig/alternatives/graphic mode="anchored" m1 Open in a separate window Figure 1 caption a7 Kaplan-Meier Estimates of Recurrence-Free Survival of Esophageal Cancer Patients (n=261) at the Johns Hopkins Hospital, according to Pathological Response at Time of Surgical Resection. table ft1 table-wrap mode="anchored" t5 caption a7 Complete Response Partial Response No Response P value Median IQR Median IQR Median IQR Within Radiation Field 5.8 4.7 - 9.3 7.1 3.5 - 18 8.5 7.5 - 62.3 0.604 Outside Radiation Field 27.3 12.3 - 31.1 5.7 3.9 - 15.8 9.1 6.9 - 14.5 0.008 Open in a separate window Median Disease-Free Survival of Patients with Recurrence (N=84) This impact of chemoradiation in preventing recurrence was of sufficient magnitude also to impact survival.

Techniques:

Kaplan-Meier Estimates of Overall Survival of Esophageal Cancer Patients who had no pathological response to neoadjuvant therapy (n=71) at the Johns Hopkins Hospital, according to whether or not there was cancer recurrence following surgical resection.

Journal: The Journal of thoracic and cardiovascular surgery

Article Title: Recurrence after Neoadjuvant Chemoradiation and Surgery for Esophageal Cancer: Does the Pattern of Recurrence Differ for Complete Responders and Those with Partial or No response?

doi: 10.1016/j.jtcvs.2009.07.069

Figure Lengend Snippet: Kaplan-Meier Estimates of Overall Survival of Esophageal Cancer Patients who had no pathological response to neoadjuvant therapy (n=71) at the Johns Hopkins Hospital, according to whether or not there was cancer recurrence following surgical resection.

Article Snippet: Thus, these data suggest that neoadjuvant chemoradiation delayed recurrence significantly and as well fewer patients failed (p=0.055). showing freedom from recurrence again underscores the fact that patients with CR have a significantly longer disease-free interval than patients with PR and NR (p=0.01). fig ft0 fig mode=article f1 fig/graphic|fig/alternatives/graphic mode="anchored" m1 Open in a separate window Figure 1 caption a7 Kaplan-Meier Estimates of Recurrence-Free Survival of Esophageal Cancer Patients (n=261) at the Johns Hopkins Hospital, according to Pathological Response at Time of Surgical Resection. table ft1 table-wrap mode="anchored" t5 caption a7 Complete Response Partial Response No Response P value Median IQR Median IQR Median IQR Within Radiation Field 5.8 4.7 - 9.3 7.1 3.5 - 18 8.5 7.5 - 62.3 0.604 Outside Radiation Field 27.3 12.3 - 31.1 5.7 3.9 - 15.8 9.1 6.9 - 14.5 0.008 Open in a separate window Median Disease-Free Survival of Patients with Recurrence (N=84) This impact of chemoradiation in preventing recurrence was of sufficient magnitude also to impact survival.

Techniques: